Back to search
FDAFDA · Food and drugs·Recall number D-0148-2024

Penicillamine Tablets USP 250 mg, 100-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202 Manufactured by: Lupin Limited, Nagpur-441 108, India, NDC# 70748-153-01

Published December 20, 2023 · Recall initiated: November 22, 2023

Summary

FDA records drug Class II recall D-0148-2024, published December 20, 2023 and initiated November 22, 2023. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: N/A; Lot: Lot # M200498, Exp. June 2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email if PENICILLAMINE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
PENICILLAMINE
Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
Product was distributed to 3 wholesale/distributor accounts.
UPC
0370748153017
Lot
Lot # M200498, Exp. June 2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Penicillamine Tablets USP 250 mg, 100-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202 Manufactured by: Lupin Limited, Nagpur-441 108, India, NDC# 70748-153-01 recalled?

Yes. FDA published recall D-0148-2024 on December 20, 2023. Reported hazard: Failed Dissolution Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: PENICILLAMINE. UPC: 0370748153017.